$-0.05
(Market cap
$169 Mln
Recently Viewed
Clear AllMarket cap
$169 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
13
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.3
Debt to Equity
0
Book Value
$0.2
EPS
$-0.4
Face value
--
Shares outstanding
111,680,087
CFO
CA$-108.70 Mln
EBITDA
CA$-167.55 Mln
Net Profit
CA$-142.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cardiol Therapeutics Inc Class A (CRDL)
| 65.7 | 70.6 | 54.9 | 62.9 | 34.9 | -13.6 | -- |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
Cardiol Therapeutics Inc Class A (CRDL)
| -25.5 | 65.3 | -72.4 | -33.5 | -39.3 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cardiol Therapeutics Inc Class A (CRDL)
|
1.6 | 168.6 | 0.0 | -33.8 | -- | -158.8 | -- | 13.0 |
| 3.3 | 34.2 | 0.0 | -11.6 | -- | -19.7 | -- | 0.6 | |
| 3.7 | 216.4 | 363.3 | -42.5 | 0.1 | -6 | -- | 0.6 | |
| 1.2 | 512.0 | 278.4 | -326.6 | -102.3 | -52.4 | -- | 0.9 | |
| 0.4 | 2.4 | 54.7 | -11.3 | -16.3 | -516.3 | -- | 0.9 | |
| 1.8 | 95.5 | 24.5 | -30.2 | -138.5 | -105.1 | -- | 5.6 | |
| 1.5 | 205.3 | 279.9 | 18.2 | -4.3 | 4.8 | 13.3 | 0.8 | |
| 3.4 | 18.5 | 0.0 | -26.6 | -- | -289.6 | -- | 2.6 | |
| 3.4 | 18.5 | 0.0 | -26.6 | -- | -289.6 | -- | 2.6 | |
| 1.5 | 391.4 | 946.4 | -15.8 | -1.2 | -1.4 | -- | 0.5 |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III... multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Read more
President, CEO & Director
Mr. David G. Elsley MBA
President, CEO & Director
Mr. David G. Elsley MBA
Headquarters
Oakville, ON
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cardiol Therapeutics Inc Class A (CRDL) is $1.58 (NASDAQ) as of 22-Apr-2026 11:38 EDT. Cardiol Therapeutics Inc Class A (CRDL) has given a return of 34.91% in the last 3 years.
Since, TTM earnings of Cardiol Therapeutics Inc Class A (CRDL) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.45
|
4.64
|
|
2024
|
-2.51
|
3.73
|
|
2023
|
-2.54
|
1.91
|
|
2022
|
-1.41
|
0.83
|
|
2021
|
--
|
--
|
The 52-week high and low of Cardiol Therapeutics Inc Class A (CRDL) are Rs 1.71 and Rs 0.88 as of 22-Apr-2026.
Cardiol Therapeutics Inc Class A (CRDL) has a market capitalisation of $ 169 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Cardiol Therapeutics Inc Class A (CRDL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.